Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASH 2025 | An update on research into JNJ-90014496 for DLBCL

Krish Patel • 8 Dec 2025
ASH 2025
Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma CAR-T JNJ-90014496

Krish Patel, MD, Sarah Cannon Research Institute, Nashville, TN, comments on ongoing research into the use of JNJ-90014496 for diffuse large B-cell lymphoma (DLBCL). This product is a CD19/CD20-targeting autologous CAR T-cell that will be investigated in an upcoming Phase III trial. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Krish Patel

Outpatient use of liso-cel in patients with R/R LBCL: real-world data from the CIBMTR registry
1:14
Outpatient use of liso-cel in patients with R/R LBCL: real-world data from the CIBMTR registry
Krish Patel • 8 Dec 2025
Quality improvement initiative to optimize AE management for bispecifics for DLBCL in the community
1:15
Quality improvement initiative to optimize AE management for bispecifics for DLBCL in the community
Krish Patel • 8 Dec 2025
Phase I trial of LY4152199, a BAFF-R-targeting bispecific, in previously treated B-cell malignancies
0:56
Phase I trial of LY4152199, a BAFF-R-targeting bispecific, in previously treated B-cell malignancies
Krish Patel • 8 Dec 2025
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
1:01
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
Krish Patel • 4 Sep 2025

Related Videos

Lisocabtagene maraleucel in R/R MZL: findings from the Phase II TRANSCEND study
1:15
Lisocabtagene maraleucel in R/R MZL: findings from the Phase II TRANSCEND study
Krish Patel • 8 Dec 2025
Optimizing the manufacturing and delivery of LV20.19 CAR T-cells for R/R DLBCL and FL
3:22
Optimizing the manufacturing and delivery of LV20.19 CAR T-cells for R/R DLBCL and FL
Krish Patel • 6 Dec 2025
Primary results from the Phase III EPCORE FL-1 trial: epcoritamab plus R2 versus R2 for R/R FL
5:28
Primary results from the Phase III EPCORE FL-1 trial: epcoritamab plus R2 versus R2 for R/R FL
Krish Patel • 6 Dec 2025
The CRS-RS.5p predictive model of CRS after glofitamab treatment in patients with R/R DLBCL
2:08
The CRS-RS.5p predictive model of CRS after glofitamab treatment in patients with R/R DLBCL
Krish Patel • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals